KZIA Kazia Therapeutics

$KZIA Thank you Mr. Dan Carlson Zoom Calls Last week we had a great call with Kazia. I've decided to open this up for broader viewing. Click on this link to see the video. Zoom calls are a service for premium subscribers and are available on replay for up to six months.

$KZIA noted first patient dosed in Sovargen's Phase 1b/2a paxalisib trial for rare epilepsy, unlocking a $2M milestone.

$KZIA Dauntless Investment Group filed an amended Schedule 13G/A reporting beneficial ownership of 842,340 KZIA ADSs, or 5.4% of the company, based on 15,598,889 ADSs outstanding. The ownership event occurred September 25 and the filing was accepted by the SEC today. This is notable because Dauntless had reported essentially exiting KZIA at the end of 2025—just 1 ADS / 0.0% in its February filing. Its 13F history then shows rebuilding the position to about 79,832 ADSs in Q1 2026 and 354,208 in Q2. The new 842,340-share disclosure therefore represents a substantial further increase.

$KZIA John Friend as much as confirmed in the interview with Dan that more data will be published at SABCS. Current timelines: 30 October: Abstract Titles Released Online 23 November: Full Abstract Text Released Online

$KZIA Can this be the long awaited reversal day? Unbelievable weakness post the financing. I get that people don't like warrants but the overhang is now 100% higher than the share price...that shouldn't scare anyone. I continue to add. I'm a masochist I guess...

$KZIA A range of recent activities of the company, have been detailed & presented to the regulator in Australia ( that organization is called, or abbreviated to ASIC )- for possible compliance breaches. The immediate goal is to see the replacement of the CEO by the Kazia Board, as a direct result of adverse ASIC findings. The recent toxic fund raising may breach previous disclosures made, in relation to timing & authority of the company for incessant and continuous issue of new shares. A formal agreement is in place for development of paxalisib as a potential cure for Parkinson's. Studies have successfully matured in PD and compelling new evidence is to hand that the Michael J Fox Foundation will fully fund a clinical trial. A strong case has been presented to ASIC that the company has not meet continuous disclosure obligations, specifically relating to its February 2025 Parkinsons Disease collarbrator announcement. A dramatic & decisive SP turnaround... should the CEO exit.

$KZIA I will stick my neck out and declare that a bottom has finally been put in. The shorts did their thing on the ill-conceived financing that everyone hated. Time to re-build. Story intact

$KZIA Existing investors in denial at the shameful way the company has treated them- while judging by the price action, others have just sold. Almost to the week, when the SP was moving & finally casting aside the shackles of years of additional stock dilution, what do they do....break disclosures of no more raises until 2028 ( despite $35m in cash), and flood the market with another up to 72% more stock. Multi issues abound as to the absolute stupidity of a raise now & the overhang the warrents create. The most historic, senseless and dumb decision ever recorded on a bouse-may not be an over statement. Why raise prior to a FDA meeting to discuss accelerated approval for GBM ? Independent of this woeful company, there is a very genuine chance of success. Spoon fed a golden opportunity in world standard work done for Paxalisib to treat Parkinson's - too busy ? we don't know, because they breach their continuous disclosure obligations, by not updating news on the PD collarbratorion.

$KZIA "Under U.S. securities laws, "manipulation" has a very strict, narrow legal definition that requires proof of deception, fraud, or artificiality. Because institutional investors and corporate management operate under the umbrella of "corporate governance" and "influence," they can legally exert massive pressure on a stock's price and a company's direction without it ever crossing the legal threshold into manipulation. [1, 2, 3] This legal boundary creates an enormous gap between what the public perceives as "manipulation" and what the Securities and Exchange Commission (SEC) can actually prosecute."

$KZIA it's heading towards thanksgiving again and needs to explain why his Kazia investment hasn't generated generational wealth yet. It's been over 7 years 😆

$KZIA didn’t you mention two weeks ago that you sold all your shares and won’t post anything here in this chat?

$KZIA Have sold my shares & won't post again. The SP upside is capped by the potential issue of additional 40% more stock- associated with the warrents overhang. In 25 years of full time trading-this is the worst raise seen. The company had $30m cash & breached a key disclosure of no more new shares until 2028 - and post an additional new stock issue/ raise of 5 TIMES in early Dec last. Furthermore, company incompentence manifests itself to an even greater degree by not embracing the existing collarbrator dynamic research, that PI3K mTOR (specifically paxalisib), can strongly reduce aSYN in Parkinson's Disease. Of course, nobody would be aware a preclinic drug to treat aSYN just sold for $200m. Kazia under CEO John Friend has been spoon fed a highly valuable, advanced & likely funded PD opportunity. A new CEO would see an immediate return however. Genentech & QIMR have equity in paxalisib via license agreements, but based on pier recent PI3 K deals, pAX is worth $3.X b gross.

$KZIA Hey , are you familiar with the concept of "resource management" as it pertains to small biotech microcaps in early drug development phase? I mean you were bitching about the recent ill-advised financing. Do you want more dilution? You can't have it both ways my friend. PD has no partnered trial to fund an unproven hypothesis that reducing alpha-synuclein would be indicative of a clinical response. Has MJFF committed to fund a clinical trial? You are quoting academia in Israel. This requires massive $ that a non-profit would have to fund to justify further investment(Hindreds of Million $). Little Kazia has lower hanging fruit and a full plate. We know you are venting but you are also chirping nonsense. Give it up on the PD and Alzheimers early concept stuff. Develop within the company's means strategically . Bash JF for doing a dumb deal but be fair

$KZIA appreciate McGrupp, usually a good indicator manipulators are active and they are running low on funds to manipulate with, so they hire the like of McGrupp, which is often an indicator of MM desperation knowing they have to eat their own short and buy back soon enough. Of course, that is unless a bunch of actual people are dumb enough to sell into a short… instead of planning ahead and buying into it.

$KZIA now has JPMorgan as its sole ADR depositary, issuing ADS each representing 500 shares under a new deposit agreement.

$KZIA dark pool soon to moon. Gotta happen wen gloom and doom is maxed. Zoom zoom will burst onto the tape 🔥🔥🔥

$KZIA Input from A I -"...no drug has ever been approved by the FDA based on a reduction of alpha-synuclein. While the protein remains a massive focus for potential disease-modifying therapies, historically, translating reductions in alpha-synuclein to actual clinical response has been a major hurdle. Multiple late-stage candidate drugs targeting this protein have faced mixed or negative results in Phase II clinical trials. However, the hypothesis is not dead: Roche’s prasinezumab advanced to Phase III testing as of mid-2025, meaning the industry is still actively trying to prove a definitive link between clearing the protein and stopping the disease." "...The Michael J. Fox Foundation (MJFF) has formally funded Kazia Therapeutics. In early 2025, Kazia received a research grant from the Michael J. Fox Foundation to fund a collaboration with The Hebrew University of Jerusalem. .."

$KZIA a lot of games… this is very typical and expected. MMs love traders, not investors, and they make money when you sell for a loss. I’m not day trading I have invested.

$KZIA this is fucking insane as always...they better hire good management team and PR team..

$KZIA "Yes, gedatolisib is now on the market. The drug manufacturer, Celcuity Inc., announced that gedatolisib became commercially available in the United States on September 30, 2026, under the brand name REVTORPYK" CELC closed at $72.10 still trending down though